Pangali Sanam sold $140K of ALMS

Pangali Sanam (Chief Legal Officer) sold 5,000 shares of ALUMIS INC. (ALMS) at $28.00 ($0.14M total) on 2026-07-06.

Original reporting
SEC EDGAR · Pangali Sanam
Published Jul 8, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity. It may influence short-term sentiment, but it does not provide new operational or financial information about ALMS.

02

Market read

Traders may monitor insider activity, but this specific sale is unlikely to change valuation without accompanying company fundamentals.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, liquidity needs, or whether other planned sales occurred.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-08 after-hours; reflects sale executed 2026-07-06.

Background

This is an SEC Form 4 insider transaction for ALUMIS INC. (ALMS) by its Chief Legal Officer.

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

SEC Form 4 shows ALMS Chief Legal Officer Pangali Sanam sold 5,000 shares at $28.00 on 2026-07-06 for $140,000.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, not an earnings, guidance, or corporate event. The disclosed sale size is modest and does not indicate a company-specific catalyst.

Market effects

No clear sector read-across from a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax or diversification-driven and may not reflect negative views, especially when holdings remain substantial.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Pangali Sanam

    Chief Legal Officer who sold 5,000 shares at $28.00.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.